CIITA and melanoma: Finally, we demonstrated that pharmacological inhibition of the IFNγ‐induced CIITA pathway using dimethyl fumarate (DMF), an FDA‐approved drug for psoriasis and multiple sclerosis [26, 27, 28], effectively interferes with the adaptation mechanisms, rescues resistance formation, and restores MHC II upregulation in melanoma cells.